4.7 Article

Modified cisplatin/interferon-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma

Related references

Note: Only part of the references are listed.
Article Gastroenterology & Hepatology

Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors

Shuichiro Shiina et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)

Review Gastroenterology & Hepatology

Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?

Etsuko Hashimoto et al.

HEPATOLOGY RESEARCH (2012)

Article Gastroenterology & Hepatology

Recent trend of clinical features in patients with hepatocellular carcinoma

Yuko Nagaoki et al.

HEPATOLOGY RESEARCH (2012)

Article Oncology

Advanced Hepatocellular Carcinoma: Which Staging Systems Best Predict Prognosis?

Fidel-David Huitzil-Melendez et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Article Gastroenterology & Hepatology

Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics

Mohamed IF Shariff et al.

Expert Review of Gastroenterology & Hepatology (2009)

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Article Gastroenterology & Hepatology

Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma

Xiao-Yu Yin et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2005)

Article Gastroenterology & Hepatology

Hepatocellular carcinoma: Recent trends in the United States

HB El-Serag

GASTROENTEROLOGY (2004)

Article Oncology

New guidelines to evaluate the response to treatment in solid tumors

F Duffaud et al.

BULLETIN DU CANCER (2000)

Article Oncology

New guidelines to evaluate the response to treatment in solid Tumors

P Therasse et al.

JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)